Literature DB >> 21359651

Thrombin generation in patients with a bleeding tendency of unknown origin.

Cihan Ay1, Johanna Haselböck, Clarissa Laczkovics, Silvia Koder, Ingrid Pabinger.   

Abstract

There are a number of persons with a mild to moderate bleeding tendency, in whom no underlying bleeding disorder can be detected despite thorough investigation of all known heritable and acquired haemostatic abnormalities. Thrombin is the central enzyme in the coagulation cascade, which is important for sufficient haemostasis. The measurement of an individual's potential to generate thrombin has been proposed for estimating the individual coagulation potential and predicting a hyper- or hypo-coagulable phenotype. The aim of our study was to investigate in vivo thrombin generation in a case-control study of patients with a bleeding tendency of unknown origin and in age- and sex-matched healthy individuals. Bleeding tendency was classified according to a standardized bleeding score. Thrombin generation was measured with a commercially available assay (Technothrombin-TGA, Technoclone, Vienna, Austria). In total, 101 patients (76 female; median age [25th-75th percentile], 44 [35-60] years) and 102 controls (67 women; median age, 47 [38-55] years) were enrolled. The distribution of parameters of thrombin generation among patients and controls showed no statistically significant difference: lag phase (14.4 [11.1-18.1] vs. 14.1 [12.1-17.1] min, p = 0.720), peak thrombin (179.8 [135.6-242.6] vs. 175.1 [143.1-261.4] nM, p = 0.576), time to peak thrombin (23.6 [18.1-28.6] vs. 22.6 [18.6-27.1] min, p = 0.790), velocity index (19.7 [13.0-39.0] vs. 22.6 [14.5-36.5] nM/min, p = 0.233) and area under the thrombin generation curve (3,491 [3,069-3,880] vs. 3,414 [3,045-3,750] nM thrombin, p = 0.673). In conclusion, the thrombin generation potential in patients with a bleeding tendency of unknown origin was not different from that of healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21359651     DOI: 10.1007/s00277-011-1201-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

1.  Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.

Authors:  Oliver Königsbrügge; Günter Weigel; Peter Quehenberger; Ingrid Pabinger; Cihan Ay
Journal:  Clin Exp Med       Date:  2018-02-07       Impact factor: 3.984

2.  Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause.

Authors:  Johanna Gebhart; Sylvia Kepa; Stefanie Hofer; Silvia Koder; Alexandra Kaider; Alisa S Wolberg; Helmuth Haslacher; Peter Quehenberger; Ernst Eigenbauer; Simon Panzer; Christine Mannhalter; Ingrid Pabinger
Journal:  Ann Hematol       Date:  2016-12-26       Impact factor: 3.673

3.  Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause.

Authors:  Stefanie Hofer; Cihan Ay; Judit Rejtö; Alisa S Wolberg; Helmuth Haslacher; Silvia Koder; Ingrid Pabinger; Johanna Gebhart
Journal:  J Thromb Haemost       Date:  2019-07-15       Impact factor: 5.824

4.  Patients Referred for Bleeding Symptoms of Unknown Cause: Does Evaluation of Thrombin Generation Contribute to Diagnosis?

Authors:  Elena Holm; Eva Zetterberg; Susanna Lövdahl; Erik Berntorp
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-02-10       Impact factor: 2.576

5.  Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report.

Authors:  Francesco Rodeghiero; Ingrid Pabinger; Margaret Ragni; Rezan Abdul-Kadir; Erik Berntorp; Victor Blanchette; Imre Bodó; Alessandro Casini; Paolo Gresele; Riitta Lassila; Frank Leebeek; David Lillicrap; Diego Mezzano; Patrizia Noris; Alok Srivastava; Alberto Tosetto; Jerzy Windyga; Barbara Zieger; Mike Makris; Nigel Key
Journal:  Hemasphere       Date:  2019-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.